首页 › 基金 › BAKER BROS. ADVISORS LP › ELVN
BAKER BROS. ADVISORS LP 对 ELVN 的持仓历史
ENLIVEN THERAPEUTICS INC · 医疗保健
BAKER BROS. ADVISORS LP 在 Q3 2026 的 13F 申报中披露持有 ELVN(ENLIVEN THERAPEUTICS INC)905,191 股,市值约 US$41.5M,约占其申报组合的 0.20%,在其申报持仓中市值排名第 32 位。 BAKER BROS. ADVISORS LP 最近 11 个申报季度中有 11 个季度披露了 ELVN 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
BAKER BROS. ADVISORS LP 对 ELVN 的持仓演变
BAKER BROS. ADVISORS LP 于 Q1 2024 首次披露 ELVN 持仓:114,833 股(约 US$2.0M)。 该持仓在 Q2 2026 达到峰值 905,191 股,市值约 US$45.9M。 在 11 次申报中,BAKER BROS. ADVISORS LP 2 次增持、0 次减持、8 次保持不变。 最近一期申报(Q3 2026)显示持股 905,191 股、市值约 US$41.5M。 持仓曾出现大幅变动:Q4 2025 增持约 136% (随后一个季度股价上涨 155%)、Q1 2026 增持约 234% (随后一个季度股价上涨 29%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 114.83K | $2.02M | 新进 |
| Q2 2024 | 114.83K | $2.68M | 持有 |
| Q3 2024 | 114.83K | $2.93M | 持有 |
| Q4 2024 | 114.83K | $2.58M | 持有 |
| Q1 2025 | 114.83K | $2.26M | 持有 |
| Q2 2025 | 114.83K | $2.30M | 持有 |
| Q3 2025 | 114.83K | $2.35M | 持有 |
| Q4 2025 | 271.41K | $4.18M | 增持 |
| Q1 2026 | 905.19K | $35.48M | 增持 |
| Q2 2026 | 905.19K | $45.94M | 持有 |
| Q3 2026 | 905.19K | $41.49M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ELVN 与 13F 数据
ELVN(ENLIVEN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 56 只申报持有 ELVN,申报仓位最大的包括:ORBIMED ADVISORS LLC (US$310.6M), Polar Capital Holdings Plc (US$294.5M), Commodore Capital LP (US$150.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ELVN 的基金
- ORBIMED ADVISORS LLC 6.78M 股 · $310.64M · Q3 2026
- Polar Capital Holdings Plc 6.43M 股 · $294.53M · Q3 2026
- Commodore Capital LP 3.27M 股 · $150.13M · Q3 2026
- Vestal Point Capital, LP 3.23M 股 · $147.83M · Q3 2026
- Fairmount Funds Management LLC 1.86M 股 · $85.06M · Q3 2026
- Siren, L.L.C. 1.48M 股 · $67.62M · Q3 2026
- Bellevue Group AG 1.47M 股 · $67.34M · Q3 2026
- Logos Global Management LP 1.08M 股 · $49.51M · Q3 2026
- First Light Asset Management, LLC 1.02M 股 · $46.68M · Q3 2026
- Novo Holdings A/S 1.00M 股 · $45.84M · Q3 2026
- First Turn Management, LLC 958.70K 股 · $43.95M · Q3 2026
- SAMLYN CAPITAL, LLC 936.17K 股 · $42.91M · Q3 2026
更多关于 BAKER BROS. ADVISORS LP
常见问题
How long has BAKER BROS. ADVISORS LP held ELVN?
BAKER BROS. ADVISORS LP has disclosed ELVN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is BAKER BROS. ADVISORS LP's current position in ELVN?
As of Q3 2026, BAKER BROS. ADVISORS LP holds 905.19K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $41.49M, representing 0.20% of its reported portfolio and ranking #32.
Has BAKER BROS. ADVISORS LP been buying or selling ELVN?
In the latest 13F filing (Q3 2026), BAKER BROS. ADVISORS LP held unchanged its position in ELVN. The position peaked in Q2 2026 at 905.19K shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Commodore Capital LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.